Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI109294

Adrenergic Modulation of Pancreatic A, B, and D Cells: α-ADRENERGIC SUPPRESSION AND β-ADRENERGIC STIMULATION OF SOMATOSTATIN SECRETION, α-ADRENERGIC STIMULATION OF GLUCAGON SECRETION IN THE PERFUSED DOG PANCREAS

Ellis Samols and Gordon C. Weir

The Veterans Administration Medical Center, University of Louisville School of Medicine, Louisville, Kentucky 40202

Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky 40202

Department of Medicine, Medical College of Virginia, Richmond, Virginia 23298

Find articles by Samols, E. in: PubMed | Google Scholar

The Veterans Administration Medical Center, University of Louisville School of Medicine, Louisville, Kentucky 40202

Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky 40202

Department of Medicine, Medical College of Virginia, Richmond, Virginia 23298

Find articles by Weir, G. in: PubMed | Google Scholar

Published February 1, 1979 - More info

Published in Volume 63, Issue 2 on February 1, 1979
J Clin Invest. 1979;63(2):230–238. https://doi.org/10.1172/JCI109294.
© 1979 The American Society for Clinical Investigation
Published February 1, 1979 - Version history
View PDF
Abstract

The effects of adrenergic substances on pancreatic insular secretions were studied in a completely isolated canine pancreas with exclusion of the duodenum from the perfusion circuit. To ensure adequate blockade, blockers were infused before agonists. A dose range of β-receptor blockade was tested, and putative α-adrenergic effects were confirmed by combined α- and β-adrenergic receptor blockade.

β-Adrenergic agonism (2 ng/ml isoproterenol) induced a mean integrated increase of 79±20% in somatostatin secretion, whereas glucagon and insulin secretion were increased by 185±45 and 495±146%, respectively. The stimulations of D, A, and B cells were abolished by propranolol.

α-Adrenergic agonism (10 ng/ml epinephrine) after β-adrenergic blockade) moderately decreased somatostatin (−37±7%) secretion, moderately increased glucagon (91±19%), and markedly decreased insulin (−85±3%) release. Similar effects on D-, A-, and B-cell secretion were induced with 2 ng/ml epinephrine or 10 ng/ml norepinephrine after β-adrenergic blockade. The α-adrenergic effects on the D and A cell were abolished by either phentolamine or by phenoxybenzamine.

This study showed that there are indeed α-adrenergic receptors on A cells and that the secretion of glucagon, a “stress” hormone, was stimulated either by α- or β-adrenergic receptor agonism. D-cell secretion, like that of the B cell, was inhibited by α-adrenergic agonism and was stimulated by β-adrenergic agonism. However, β-adrenergic-induced changes in D-cell secretion were smaller in magnitude than those of B-cell secretion.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 230
page 230
icon of scanned page 231
page 231
icon of scanned page 232
page 232
icon of scanned page 233
page 233
icon of scanned page 234
page 234
icon of scanned page 235
page 235
icon of scanned page 236
page 236
icon of scanned page 237
page 237
icon of scanned page 238
page 238
Version history
  • Version 1 (February 1, 1979): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts